- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07686198
Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
A Randomized, Double-Blind, Vehicle-Controlled, Split-Arm Study of Twice Daily Re-Q Pro-Longevity Serum in Combination With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Andrea Pacheco
- Numero di telefono: 858-657-1004
- Email: apacheco@clderm.com
Luoghi di studio
-
-
California
-
San Diego, California, Stati Uniti, 92121
- West Dermatology Research Center/Cosmetic Laser Dermatology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Female participants aged 50 to 80 years.
- Fitzpatrick skin types I-IV.
- Moderate to severe photodamage and crepiness on the arms, based on clinical evaluation, including fine wrinkling, coarse wrinkling, photodamage, and a global assessment as assessed with the 10-point Dermatologic Assessment Form and Photographic Scale
- Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
- Willing to sign an informed consent form and photography release for research, publication, and/or commercial use.
- In good general health as determined by the investigator based on medical history and clinical judgment.
- Willing to maintain the study skincare regimen and refrain from introducing new topical or procedural treatments to the forearms during the study period.
- Negative urine pregnancy test at all visits for participants of childbearing potential.
- Participants must be of non-childbearing potential, defined as: a. History of hysterectomy or bilateral oophorectomy, or b. No menses for at least 12 consecutive months without an alternative medical cause. Or, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include: i. Oral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) ii. Intrauterine coil iii. Bilateral tubal ligation iv. Hysterectomy v. Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) vi. Abstinence (must agree to use a barrier method if sexual activity begins during the study) vii. Partner with a vasectomy (if not, participant must agree to use a barrier method)
Exclusion Criteria:
- Patients with dark hair in the treatment area who are unwilling to shave the treated area prior to IPL treatments or who are unwilling to proceed knowing IPL will eliminate at least 50% of the hairs in the treatment area
- A suntan in the treatment area or use of sunless tanner/spray-tan in the treatment areas 4 weeks prior to study treatment
- Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
- Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation on the treatment area within 30 days prior to treatment and during the study period.
- Use of GLP-1 medications or metformin within 3 months prior to enrollment
- Pregnancy, plans to become pregnant during the study period, or current breastfeeding.
- History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).
- Current or recent use (within the past 3 months) of systemic immunosuppressive medications.
- Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.
- Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
- Active smoking tobacco or use of nicotine-containing products within 6 months prior to enrollment.
- Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.
- Unwillingness to refrain from undergoing any additional aesthetic treatments to the arms (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.
- History of keloids or scarring/tattoos in the treatment area
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Group A Right Arm Treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy
Subjects will pre-treat for two weeks with the active serum, then return to office for the first IPL treatment.
They will continue to use the serum and return four weeks later for the second IPL treatment.
|
Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy
|
|
Comparatore fittizio: Group B Left Arm Treated with Vehicle serum and Intense Pulsed Light Therapy
Subjects will pre-treat for two weeks with the active serum, then return to office for the first IPL treatment.
They will continue to use the serum and return four weeks later for the second IPL treatment.
|
Left Arm treated with vehicle serum and Intense Pulsed Light Therapy
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Physician Global Aesthetic Improvement Scale (PGAIS):
Lasso di tempo: Day 84 (Week 14 Post Second Treatment)
|
Physician assessed aesthetic improvement. All assessments will be made on 5-point scale (Circle One)
|
Day 84 (Week 14 Post Second Treatment)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Participant Global Aesthetic Improvement Scale (SGAIS):
Lasso di tempo: Day 84 (Week 14 Post Second Treatment)
|
Participant assessed aesthetic improvement. All assessments will be made on 5-point scale (Circle One)
|
Day 84 (Week 14 Post Second Treatment)
|
|
10-point Dermatologic Assessment Form and Photographic Scale
Lasso di tempo: Screening and Day 84 (Week 14 Post Second Treatment)
|
Physician Assessed : (Circle One) Fine Wrinkling 0= Absent 1-2-3 = Mild 4-5-6 = Moderate 7-8-9 = Severe Coarse Wrinkling 0= Absent 1-2-3 = Mild 4-5-6 = Moderate 7-8-9 = Severe Abnormal Pigmentation 0= Absent 1-2-3 = Mild 4-5-6 = Moderate 7-8-9 = Severe Global 0= Absent 1-2-3 = Mild 4-5-6 = Moderate 7-8-9 = Severe |
Screening and Day 84 (Week 14 Post Second Treatment)
|
|
Skin Quality Assessment
Lasso di tempo: Screening and Day 84 (Week 14 Post Second Treatment)
|
Physician Assessed Skin Quality Assessment (SQS) Grading System (5-point scale) Circle One: Grade 0 - Excellent • Smooth, even skin • Firm and elastic • No visible crepiness or fine lines • Well-hydrated, healthy appearance Grade 1 - Good • Mild textural irregularity • Very subtle fine lines or early crepiness • Good firmness with minimal laxity • Overall youthful appearance Grade 2 - Fair • Noticeable texture changes • Early crepey appearance, especially with movement or pinching • Mild laxity or loss of elasticity • Skin may appear thinner or less hydrated Grade 3 - Poor • Obvious crepiness at rest • Moderate laxity • Fine lines clearly visible • Uneven surface texture and reduced resilience Grade 4 - Very Poor • Severe crepiness • Marked laxity and thinning • Prominent fine wrinkling • Dull, fragile, or atrophic appearance |
Screening and Day 84 (Week 14 Post Second Treatment)
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IIT-Rapalogix-2026
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Pelle fotodanneggiata
-
University of ArizonaNon ancora reclutamentoGruppo 1: Carrier Care (CC) seguito da Skin-to-Skin Care (SSC) seguito dalla scelta della famiglia | Gruppo 2: cura della pelle a pelle (SSC) seguito da Carrier Care (CC) seguito dalla scelta della famiglia
-
Aalborg UniversityCompletatoPrurito | Papaina | Skin Prick Test (SPT)Danimarca
-
Mastelli S.r.l1MedReclutamentoElasticità della pelle | Idratazione della pelle in volontari sani | Miglioramento estetico della pelle | Skin Turgor | Soddisfazione del soggettoItalia
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletatoRinocongiuntivite allergica al polline di betulla | Con un Skin Prick Test positivo al polline di betullaFrancia